ST 1481 clinical trials
Also written Gimatecan, ST1481 and LBQ707.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2002
How each study uses ST 1481 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 2
Lee's Pharmaceutical Limited (4) · Novartis Pharmaceuticals (3) · Sigma-Tau Research, Inc. (2) · M.D. Anderson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Novartis (1)
Studies
Open first, then newest update. How each study uses ST 1481 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal CancerStatus unknownPhase 2Lee's Pharmaceutical LimitedNCT04846842Written as GimatecanHow we know
- A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.CompletedPhase 1Novartis PharmaceuticalsNCT00410358Written as GimatecanHow we know
- An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid TumorCompletedPhase 1Novartis PharmaceuticalsNCT00441610Written as GimatecanHow we know
- A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic CancerStatus unknownPhase 2Lee's Pharmaceutical LimitedNCT04571489Written as GimatecanHow we know
- A Study of Gimatecan (ST1481) in Small Cell Lung CancerStatus unknownPhase 2Lee's Pharmaceutical LimitedNCT04501029Written as GimatecanHow we know
- A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerStatus unknownPhase 1Lee's Pharmaceutical LimitedNCT04029909Written as Gimatecan 0.6mg/m2/dHow we know
- Phase I Study of Gimatecan in Patients With Myelodysplastic SyndromesCompletedPhase 1M.D. Anderson Cancer CenterNCT00493571Written as GimatecanHow we know
- Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant GliomaCompletedPhase 1/2Jonsson Comprehensive Cancer CenterNCT00087061Written as gimatecanHow we know
- Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT00420485Written as gimatecanHow we know
- A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid TumorsCompletedPhase 1NovartisNCT00487058Written as GimatecanHow we know
- This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.CompletedPhase 1/2Sigma-Tau Research, Inc.NCT00032903Written as Gimatecan® (ST 1481)How we know
- This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid TumorCompletedPhase 1Sigma-Tau Research, Inc.NCT00033202Written as Gimatecan® (ST-1481)How we know